Oncotarget

Research Papers: Immunology:

Development of interleukin-17-producing Vγ2+ γδ T cells is reduced by ICOS signaling in the thymus

Terkild Brink Buus _, Jonas Damgård Schmidt, Charlotte Menné Bonefeld, Carsten Geisler and Jens Peter Holst Lauritsen

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:19341-19354. https://doi.org/10.18632/oncotarget.8464

Metrics: PDF 1741 views  |   HTML 2453 views  |   ?  


Abstract

Terkild Brink Buus1, Jonas Damgård Schmidt1, Charlotte Menné Bonefeld1, Carsten Geisler1 and Jens Peter Holst Lauritsen1

1 Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Correspondence to:

Terkild Brink Buus, email:

Keywords: γδ T cell, development, thymus, ICOS, interleukin-17, Immunology and Microbiology Section, Immune response, Immunity

Received: September 30, 2015 Accepted: March 21, 2016 Published: March 29, 2016

Abstract

Co-stimulation is an integral part of T cell signaling involved in almost all facets of T cell biology. While much is known about co-stimulation in differentiation and function of conventional αβ T cells, less is known about how co-stimulation affects the development and programming of γδ T cells. In this study, we have investigated the role of inducible T cell co-stimulator (ICOS) on the development of γδ T cells. We show that ICOS is expressed by a population of immature Vγ2+CD45RBlow γδ T cells predisposed to interleukin-17 (IL-17) production. We found that treatment with ICOS specific antibodies drastically reduces fetal development of IL-17-producing γδ T cells by agonistic actions, and that ICOS deficient mice have a significant increase in the population of IL-17-producing Vγ2+ γδ T cells in the thymus, spleen, lymph nodes and skin and exhibit exacerbated sensitization responses to 2,4-dinitrofluorobenzene. In conclusion, this study demonstrates that development of IL-17-producing Vγ2+ γδ T cells is reduced by ICOS signaling in the thymus.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8464